Aarti Industries delivered a resilient Q3 FY26 performance characterized by strong volume growth and record export contributions. Management highlighted three structural tailwinds: the India-EU FTA, China's shift away from hyper-competition ('anti-involution'), and the US-India trade deal. While Agrochemicals and Pharma remain pressured by Chinese dumping, the Energy (MMA) and Polymer segments are seeing robust demand and capacity expansions.
vs Q4 FY26
Notable Quotes from the Call
Most Confident Moment
Management's clear articulation of the 360 KT MMA capacity target and the immediate 7-10% price benefit from China's VAT rebate removal.
Least Confident Moment
Hesitation to provide a long-term capacity target for MMA beyond the immediate debottlenecking phase.
| Metric | Value | YoY |
|---|---|---|
| Revenue | ₹2.5K Cr | — |
| EBITDA | ₹323 Cr | — |
| PAT | ₹133 Cr | — |
| Export Revenue Share | 65% | — |
| Exceptional Expense (NLC) | ₹15 Cr | — |
Segment Breakdown
| Metric | Latest | Trend |
|---|---|---|
| Revenue(crores) | 2422 | |
| EBITDA(crores) | 342 | |
| PAT(crores) | 137 |
| Category | Target | Priority |
|---|---|---|
| Capacity | MMA Capacity→360 KT | High |
| Capacity | DCB Capacity→140 KTPA | High |
| Capex | Annual CAPEX→₹1,100 crores | High |
| Capex | Zone 4 Total CAPEX→₹1,600-1,800 crores | High |
| Capex | FY27 CAPEX→Significantly lower | Medium |
| Revenue | JV Revenue Potential→₹300-400 crores | Medium |
| Severity | Risk |
|---|---|
medium | Chinese Dumping in Agro/Pharma Agrochemicals and Pharmaceuticals continue to see subdued pricing due to persistent dumping by China. Management |
low | Working Capital and Debt Increase Increase in exports has resulted in higher working capital, leading to a marginal increase in debt and interest costs. Management |
medium | MMA Margin Volatility MMA margins are sensitive to the spread between gasoline and phosphates; management is focusing on value chain integration to stabilize this. Analyst |
Areas of Evasion(1)
Management identified three major events positively impacting the sector: the India-EU FTA, China's 'anti-involution' strategy, and the US-India trade deal. The US-India deal is particularly significant, as it reduces tariffs from over 50% to approximately 18% for key products. This shift is expected to boost volumes and margins in the US market, where Aarti already resumed record volumes in Q3 FY26.
The Energy business, led by MMA, remains the primary growth driver. The company is scaling capacity from 290+ KT to 360 KT by Q4 FY26 through efficient debottlenecking. While MMA currently constitutes a large portion of the portfolio, management expects it to settle at 30-40% in the medium term as other Zone 4 projects come online. They are also exploring backward and forward integration to stabilize volatile margins in this segment.
Zone 4 represents a total investment of ₹1,600 to ₹1,800 crore, with the majority to be deployed by the end of FY26. Key projects including MPP, Chloro toluene, and downstream process blocks are set to commission in a phased manner during CY26. These assets utilize in-house indigenous technology, which management claims allows them to be among the lowest-cost producers globally.
Aarti is seeing immediate benefits from China's policy shift to curb hyper-competition. Specifically, the removal of the 13% VAT rebate on Chinese exports in the NCB chain led to a 7-10% price increase in global markets within days. Management anticipates this transition will serve as a structural catalyst for sustainable margin recovery across their broader portfolio as China prioritizes higher-quality growth.
FY26 CAPEX is estimated at ₹1,100 crore, slightly above the previous guidance of ₹1,000 crore due to fast-tracked initiatives in MMA and DCB. However, management expects FY27 CAPEX to be significantly lower as the current heavy investment cycle for Zone 4 nears completion. Operating cash flow for the first nine months of FY26 stood between ₹500-600 crore, supporting the ongoing expansion.